Shield Therapeutics has appointed James Karis as non-executive chairman of the company, with immediate effect.
Shield Therapeutics has appointed James Karis as non-executive chairman of the company.
James has served on Shield’s board of directors for almost three years as a member of the Audit and Nominations Committees and as chair of the Remuneration Committee. A proven entrepreneur, he brings to Shield over 35 years of experience in the pharmaceutical, healthcare services, technology and medical device industries. He is also a seasoned board member for both public and private companies with extensive experience in corporate strategy, M&A and all aspects of company financing, particularly with respect to the US market.
James commented on his new position: “It is exciting to take on an expanded role as Chairman of Shield Therapeutics during a time when the Company has several important milestones on the horizon. I look forward to working with the rest of the Board and management team in continuing our efforts to provide a unique therapy benefiting patients around the world while making Shield a success for its shareholders.”